Compare Neurocrine Biosciences Inc (NBIX) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs SYSCO Corporation — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while SYSCO Corporation trades at $78.14 (market cap $38.47B). The key difference: SYSCO Corporation is far larger — about 2.7× Neurocrine Biosciences Inc's market cap, and SYSCO Corporation pays a 2.81% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and SYSCO Corporation for 77 Days on average.
| NBIX | SYY | |
|---|---|---|
Market Cap | $14.36B | $38.47B |
Volume | 1,237,180 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $185.50 | $91.16 |
52-Week Low | $123.10 | $69.30 |
Typical Hold Time | 23 Days | 77 Days |
Enterprise Value | $14.37B | $51.65B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Sysco (SYY) trades at $78.20, up 1.84% with neutral technical signals. The company shows steady revenue growth to $81.37B in 2025, though net margins remain thin at 2.08%. Recent corporate actions include a $1.5B senior notes offering and a $500M AI efficiency program targeting cost savings. Analyst consensus is bullish with 60% buy ratings and an $85.75 price target, representing 9.6% upside potential from current levels.
Sysco presents a balanced investment case with strong institutional support and dividend stability, but faces margin pressure and high debt levels. The AI efficiency initiative and consistent revenue growth provide catalysts, while competitive pressures and economic sensitivity pose risks. Current valuation appears reasonable with P/E of 21.37 and P/S of 0.44.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
